Nuclear Medicine Market Overview
The global nuclear medicine market size was valued at $5.5 billion in 2023, and is projected to reach $16.1 billion by 2033, growing at a CAGR of 11.3% from 2024 to 2033.
Growing prevalence of cancer and cardiovascular diseases, which require advanced diagnostic and therapeutic solutions as well as increasing adoption of SPECT and PET imaging technologies and rising investments in radiopharmaceutical research are major drivers of the nuclear medicine market.
Market Size & Future Outlook
- 2023 Market Size: $5.5 Billion
- 2033 Projected Market Size: $16.1 Billion
- CAGR (2024-2033): 11.3%
- North America: Largest market in 2023
- Asia Pacific: Fastest growing market
The global nuclear medicine market is experiencing growth due to increase in incidence of cancer and cardiovascular conditions necessitating advanced diagnostics and therapies, surge in investments in healthcare infrastructure and services and development of novel radiopharmaceuticals and innovative treatment methods.
Market Introduction and Definition
Nuclear medicine refers to a vertical of medical imaging that utilizes small amounts of radioactive material to diagnose and treat different diseases. This type of treatment analyzes details about the anatomy and physiology of organs and tissues using radiopharmaceuticals. Nuclear medicine provides information about the functioning of organs and tissues at a molecular level. This allows for early detection of disease and makes way for accurate treatment planning.
It is used in diagnostic imaging, which is used to assess conditions related to cancer, heart disease, and neurological disorders. These methods work by introducing a radiopharmaceutical into the body of a patient. A specialized camera then detects the radiation emitted and creates images that reveal abnormal biological activity.
It is also used in cancer diagnosis and management. PET scans help detect tumors, determine the stage of cancer, evaluate treatment effectiveness, and monitor disease recurrence. Further, nuclear medicine also plays an important role in cardiology. It helps assess blood flow to the heart and evaluate the functioning of the heart. Advancements in nuclear medicine help enhance the accuracy of diagnosis. Improvements in detector technology, image processing software, and artificial intelligence make way for faster scans, clearer images, and better interpretation. These innovations help improve clinical efficiency and patient comfort while reducing radiation exposure.
Key Takeaways
The nuclear medicine market size study covers 20 countries. The research includes a segment analysis of each country in terms of value ($Billion) for the projected period 2024-2033.
More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major nuclear medicine industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
global nuclear medicine market is experiencing growth due to several factors such as increase in incidence of cancer and cardiovascular conditions necessitating advanced diagnostics and therapies, higher investments in healthcare infrastructure and services and development of novel radiopharmaceuticals and innovative treatment methods.
Why Is Demand Increasing in Nuclear Medicine Market?
Rise in aging popular and increase in prevalence of chronic diseases drive the demand for nuclear medicine. The techniques used in nuclear medicine provide molecular-level insights that are not provided by traditional imaging methods. This helps clinicians to detect disease at its early stages and plan the treatment effectively. Further, advancements in technology drive the developments in diagnostic and therapeutic applications, which fuel investment and utilization. There is a rise in awareness about the benefits of nuclear medicine for personalized care among children and patients. This makes way for increase in demand for nuclear medicine. Also, initiatives by government that focus on improving cancer care infrastructure drive the growth of the nuclear medicine market.
Key Market Dynamics
Drivers
Increase in prevalence of chronic diseases such as cancer and cardiovascular conditions make way for advanced diagnostic and therapeutic solutions. This fosters the need for nuclear medicine across the healthcare sector. Nuclear medicine imaging techniques such as PET and SPECT enable early detection, accurate disease staging, and effective treatment monitoring. This plays an important role in effective diagnosis and treatment. Also, there is a rise in prevalence of cancer, which increases the demand for nuclear imaging and targeted radionuclide therapies. Moreover, the prevalence of aging global population increases the need for advanced diagnostic tools. The older population is prove to chronic and degenerative diseases, which need proper diagnosis and treatment. This increases the important of geriatric care.
Technological advancements, such as the development of precise radiopharmaceuticals, also drive the market growth. Also, adoption of hybrid imaging systems such as PET/CT and SPECT/CT help improve diagnostic accuracy by combining functional and anatomical imaging. In addition, advancements in radiopharmaceutical development, artificial intelligence, and image processing software help enhance efficiency, reduce scan time, and improve treatment outcomes for the patient. This fosters the growth of the nuclear medicine market.
Challenges
However, high cost of nuclear medicine procedures and equipment limit accessibility and affordability in low- and middle-income countries. Nuclear imaging systems such as PET scanners and cyclotrons require significant capital investment. This makes them less accessible for smaller hospitals and clinics. Further, stringent regulatory requirements and lengthy approval processes for new radiopharmaceuticals delay the introduction of innovative products. Nuclear medicine involves the use of radioactive materials, which are subject to strict regulations. Approval processes for new radiopharmaceuticals is time-consuming and costly as well. This deters the growth of the market. Also, the potential health risks associated with exposure to radiation pose safety concerns hinder the nuclear medicine market growth.
The supply chain for radiopharmaceuticals is complex as a lot of radioactive isotopes have short half-lives. This leads to proper coordination in production, transportation, and usage. Any disruption in supply can delay procedures and affect patient care. This is major challenge for the key players in the nuclear medicine market. Also, the shortage of skilled professionals limits the growth of the market.
Opportunities
Nevertheless, increase in focus on personalized medicine offers significant potential for nuclear medicine market. In addition, rise in investments in healthcare infrastructure in emerging regions, along with supportive government policies, are significant contributors toward market expansion. Integration of diagnostic imaging and targeted therapy offers growth opportunities in the oncology sector. This approach is proving to be an effective method of treatment for prostate cancer and neuroendocrine tumor. Further, advancements in artificial intelligence and digital health also foster the growth of the market. AI-powered image analysis can improve diagnostic accuracy, reduce interpretation time, and support clinical decision-making. Integration with electronic health records enhances workflow efficiency and patient management. Innovations in radiopharmaceutical sector help reduce supply chain challenges and production costs. This is anticipated to drive the growth of the nuclear medicine market during the forecast period.
Nuclear Medicine Market Segmentation Overview
The nuclear medicine industry is segmented into type, modality, application, end-user and region. On the basis of type, the market is classified into diagnostics, therapeutics, biochemistry research. Based on modality, the market is divided into SPECT, PET, Alpha-emitters, Beta-emitters and brachytherapy. As per application, the market is segregated into oncology, cardiology, neurology, thyroid, and others. Based on end user, the market is divided into hospitals & diagnostic centers and research institutes. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Who Are the Primary End Users Driving Market Adoption?
Hospitals are the major adopters of nuclear medicine. They invest in new technologies that help detect and treat cancer and other chronic diseases. Further to this list are diagnostic imaging centers, which are independent imaging providers and outpatient centers. Many patients prefer outpatient settings for convenience and affordability. These centers offer access to nuclear imaging, especially in urban and suburban regions. Cancer treatment and specialty clinics also use nuclear medicine for diagnosis, staging, and treatment monitoring. Research institutions and academic centers also use nuclear medicine technologies for clinical trials and research. Moreover, nuclear medicine is also adopted by government and private healthcare networks that standardize diagnostic pathways.
Industry Trends
- In February 2024, The (Indian) government medical college and hospital (GMCH) Nagpur has been chosen for setting up new skill labs worth US$3.51 million (Rs.29 crore) for postgraduate student and faculty especially surgeons. The latest nuclear medicine diagnostic unit is being setup at a cost of US$ 1.09 million (Rs. 9 crore) through the district planning and development.
- In October 2022, The U.S. Department of Health and Human Services spent $290 million on a drug (Nplate) to treat radiation sickness.
- In May 2024, Mauritius opened its new National Cancer Centre in Solferino, bringing an end to nearly ten years of IAEA support for the development of nuclear medicine in the nation. Anticipated to significantly transform cancer treatment for Mauritius patients, the new facility will consolidate all oncology services, including nuclear medicine, under one roof.
Patent Analysis, By Country, 2015-2024
China witnessed the highest number of nuclear medicine market share in patent approvals and applications, due to favorable government policies, new technological advancement and new product launches in the country. The U.S. has 14.5% of the total number of patents, followed by Japan at 9.3% and PCT at 8.9%.
Competitive Landscape
The major players operating in the nuclear medicine market include GE Healthcare, Jubilant Life Sciences Ltd, Nordion (Canada) , Inc., Bracco Imaging S.P.A, The Institute for Radioelements (IRE) , NTP Radioisotopes SOC Ltd., The Australian Nuclear Science and Technology Organization (ANSTO) , Eczacibasi-Monrol, Lantheus Medical Imaging, Inc., and Eckert & Ziegler. Other players in nuclear medicine market includes Mallinckrodt, Cardinal Health, Telix Pharmaceuticals, Inc., Nordic Nanovector, Y-mAbs Therapeutics, Inc., NorthStar Medical Radioisotopes, FUJIFILM Toyama Chemical Co., Ltd., ITM Isotope Technologies Munich SE, Penang Adventist Hospital (PAH), Navidea Biopharmaceuticals, Inc. and so on.
Who Are the Key Players in the Market and What Are Their Strategies?
Key players in imaging hardware include firms that develop PET, SPECT, and hybrid imaging systems. These companies invest in research and development to help improve resolution, speed, and workflow efficiency. The focus is to expand the business through partnerships with hospitals and imaging centers. This is done offering service contracts and financing options to lower entry barriers.
Radiopharmaceutical producers supply the radioactive tracers used in diagnostics and therapy. These firms invest in expansion of radiotracers as well as adherence to regulatory approvals across multiple regions. They adopt partnership with clinical research organizations and academic institutions as their key growth strategy. This helps them validate new tracers and increase commercialization.
Software and data analytics companies also play an important role in the nuclear medicine sector. These companies offer AI-enabled tools that improve image interpretation and automate routine tasks. These players adopt collaboration as their key growth strategy. They focus on collaboration with imaging hardware manufacturers to create integrated solutions.
Key Strategies and Developments
- In December 2023, Eli Lilly and Company finalized an agreement to acquire POINT Biopharma, Inc., a prominent radiopharmaceutical company.
- In November 2023, BWXT Medical, a subsidiary of BWX Technologies, aimed to focus on supply Fusion Pharmaceuticals with generators for producing actinium-225, a crucial medical isotope in cancer treatment trials. This agreement grants Fusion a preferential radium-225 supply and access to advanced generator technology, supporting the manufacturing of Ac-225 for clinical trials.
- In March 2023, Life Healthcare acquired TheraMed Nuclear to expand in South Africa for non-clinical imaging operations in Gauteng.
- In August 2021, NorthStar Medical Radioisotopes, LLC, and GE Healthcare announced to sign an agreement for manufacturing and distribution of iodine-123 (I-123) capsules in the U.S.
What are the Key Benefits for Stakeholders
- This report provides a quantitative analysis of the nuclear medicine market trends, current trends, estimations, and dynamics of the nuclear medicine market analysis from 2023 to 2033 to identify the prevailing nuclear medicine market opportunities.
- The nuclear medicine market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the nuclear medicine market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global nuclear medicine market statistics.
Key Sources Referred
- Centers for Disease Control and Prevention
- World Health Organization
- National Center for Biotechnology Information
- The Lancet
- National Perinatal Epidemiology and Statistics Unit (NPESU)
- Science Direct
- Health Resources and Services Administration (HRSA)
- Department of Health and Human Services (HHS)
- National Institutes of Health (NIH)
Nuclear Medicine Market Report Highlights
| Aspects | Details |
 Market Size By 2033 | USD 16.1 Billion |
 Growth Rate | CAGR of 11.3% |
 Forecast period | 2024 - 2033 |
 Report Pages | 260 |
 By Type |
|
 By Modality |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | The Institute for Radioelements, Bracco Imaging S.P.A, Eckert and Ziegler, Lantheus Medical Imaging, Inc.,, Jubilant Life Sciences Ltd, The Australian Nuclear Science and Technology Organization, Eczacibasi-Monrol, GE Healthcare, Nordion, Inc., NTP Radioisotopes SOC Ltd. |
Analyst Review
Radiopharmaceuticals is a medical specialty that uses specific radiotracers, and have emerged as an efficient imaging technology in the field of nuclear medicine. The non-invasive nature of radiopharmaceuticals has quickened the diagnosis of various diseases such as cardiovascular diseases, neurological disorders, and cancers. Nowadays, therapeutic radiopharmaceuticals are preferred to conventional therapeutic modalities, such as chemotherapy, in the field of oncology for treating cancers. Radiopharmaceuticals are mostly used in diagnostic applications due to advancements in the field such as hybrid imaging technologies using PET/CT and SPECT/CT.
Convenient therapeutic radiopharmaceuticals procedures have a higher capability of mapping physiological functions and metabolic activities and providing specific information about organ function and dysfunction as compared to conventional imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasonography (US) among others. Furthermore, increase in incidence of cancer & cardiovascular aliments, growing demand for alpha radio immunotherapy-based targeted cancer treatment, need for nuclear imaging techniques, and advancements in radiotracers have opened new avenues for radiopharmaceutical manufactures.
The SPECT and PET radiopharmaceuticals modality are widely used at hospitals and diagnostics centers adopting novel methods of radiolabeling with advanced targeting specificity and better therapeutic efficacy. Therefore, the use of SPECT and PET scans facilitates early and accurate diagnosis of complex diseases such as cancer. Increased usage of SPECT and PET scans in turn fosters the demand for radiopharmaceuticals across varied applications such as cancer, cardiac diseases, neurological diseases, and renal & respiratory diseases, among others. The steady progress in the field of nuclear medicine is expected to continue in the near future, which would eventually help in improving the medical diagnostic sector.
Positron emission tomography (PET) scans are widely used in the medical sector, as they provide better quality images and higher precision diagnosis. The other reasons attributed to the high demand for PET scans include upsurge in R&D activities, especially in developing economies, and wide scope of radiopharmaceutical applications such as thyroid, oncology, and bone pain palliation. The radiopharmaceutical market is dominated by Asia-Pacific region followed by Europe and North America. However, Asia-Pacific region is growing at fastest pace during the study period due to large pool of targeted diseases with unmet medical demands in China and India. The Asia-Pacific radiopharmaceuticals market would offer lucrative growth opportunities to the market players due to improvement in healthcare infrastructure, high disposable incomes, and increasing government initiatives to promote early diagnosis of diseases.
The global nuclear medicine market is experiencing growth due to several factors such as increase in incidence of cancer and cardiovascular conditions necessitating advanced diagnostics and therapies, higher investments in healthcare infrastructure and services, and development of novel radiopharmaceuticals and innovative treatment methods.
Nuclear medicine is a specialized area of medical imaging that uses small amounts of radioactive material to diagnose, determine the severity of, or treat a variety of diseases, including many types of cancers, heart disease, gastrointestinal, endocrine, and neurological disorders.
The GE Healthcare, Jubilant Life Sciences Ltd, Nordion (Canada) , Inc., Bracco Imaging S.P.A, The Institute for Radioelements (IRE) , NTP Radioisotopes SOC Ltd. held a high market position in 2023.
The base year is 2023 in nuclear medicine market.
The forecast period for nuclear medicine market is 2024 to 2033.
The market value of nuclear medicine market in 2033 is $16.1 billion.
The total market value of nuclear medicine market is $5.5 billion in 2023.
Loading Table Of Content...
